A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Phase I single-institution, open-label, dose-escalating, clinical and pharmacokinetic study.
The purpose is to determine the safety, tolerability and to identify the dose limiting
toxicities(DLT) and recommended dose (RD) of PM02734 administered every 3 weeks,
intravenously, over 30 minutes to subjects with advanced malignant solid tumors.